Status:
COMPLETED
Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia
Lead Sponsor:
Shaheed Zulfiqar Ali Bhutto Medical University
Conditions:
Cytokine Release Syndrome
Covid-19 Pneumonia
Eligibility:
All Genders
18+ years
Brief Summary
Tocilizumab (TCZ), interleukin-6 (IL-6), newly appeared as treatment of cytokine release syndrome (CRS) in patients with severe covid-19 associated pneumonia. In the present study, we aimed to discuss...
Detailed Description
This observational study was designed just to visualize the efficacy and safety of Tocilizumab, an antibody anti-IL-6 receptor in patients with moderate to severe COVID-19 with increased inflammatory ...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old; Clinical diagnosis of SARS-CoV-2 virus by PCR, or by other approved diagnostic methodology, or, with presumptive diagnosis of COVID-19 (other respiratory causes ruled out and COVID-19 test pending); Hospitalized with COVID-19-induced pneumonia; Elevated CRP, D-Dimers or ferritin levels; Bodyweight ≥ 40kg.
Exclusion
- Eligible patients must not have a history of hypersensitivity to any drugs or metabolites of similar chemical classes as canakinumab; Use of tocilizumab within 3 weeks prior; Suspected or known active bacterial, fungal, or parasitic infection (besides COVID-19); Patients with significant neutropenia (ANC \<1000/mm3); Treatment with an investigational drug within 5 half-lives or 30 days (whichever is longer) prior to tocilizumab dose.
Key Trial Info
Start Date :
April 28 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 22 2020
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04873141
Start Date
April 28 2020
End Date
June 22 2020
Last Update
May 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shaheed Zulfiqar Ali Bhutto Medical University
Islamabad, Pakistan, 44000